Combination immunotherapy improves survival in mouse models of mesothelioma

(Massachusetts General Hospital) Massachusetts General Hospital investigators have found that combined treatment with two cancer immunotherapy drugs -- one a novel immune modulator and one that focuses and activates the anti-tumor immune response -- significantly prolonged survival in mouse models of the aggressive cancer malignant mesothelioma.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news